Singapore Institute of Advanced Medicine Holdings (SAM) has partnered with ProNova Solutions on the setting-up of a new proton therapy facility in Singapore.
The new cancer and proton centre, which involves the investment of around $100m, will be constructed at the Biopolis Campus in the country.
Go deeper with GlobalData
SAM founder and chairman Djeng Shih Kien said: "We believe proton therapy is a significant step forward in our treatment of cancer and ProNova has proven to be the best partner with next generation technology."
As part of the deal, ProNova will equip the new centre with two superconducting gantry proton treatment rooms, including an additional room for research.
Each treatment room features Fast Scanning IMPT technology with integrated 3D imaging, which offers edge pencil beam delivery with imaging capability. It allows physicians and therapists to minimise collateral damage to healthy tissue and increase dosage to the tumour.
The company will also install its SC360 proton therapy system at the new outpatient cancer centre.
ProNova Solutions chairman and CEO Terry Douglass said: "We look forward to providing our unique total solutions offerings and sharing our proton therapy knowledge and clinical experience with SAM’s staff.
"We believe that the new developments in proton therapy and other cancer treatment technologies accomplished at the SAM ProNova Biopolis Cancer Center will be a major step in redefining the future of cancer treatment."
Biopolis campus also houses the research and development centres of pharma companies such as Abbott, GlaxoSmithKline, Lilly, Novartis, Schering-Plough and Takeda.
Proton therapy is a form of radiation therapy, which uses a single beam of high-energy protons for the treatment of different types of cancers.
